REFERENCES
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, the Hospital Infection Control Practices Committee. Guideline for the prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20: 247–280.
- Song F, Glenny AM. Antimicrobial prophylaxis in col-orectal surgery: a systemic review of randomised controlled tri-als. Health Technol Assessment 1998; 2: 1–56.
- Kernodle DS, Kaiser AB. Postoperative infections and antimicrobial prophylaxis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles andPractice of Infectious Diseases, 4th Edition. New York: Churchill Livingstone, 1995: 2742–2756.
- Wilson KH. The gastrointestinal microflora. In: Yamada T, ed. Textbook of Gastroenterology, 2nd Ed. Philadelphia: JB Lippincott Co. 1995: 607–618.
- Guglielmo BJ, Hohn DC, Koo PJ, Hunt TK, Sweet RL, Conte JEJr. Antibiotic prophylaxis in surgical prophylaxis. Arch Surg 1983; 118: 943–955.
- Nichols RL, Smith JW, Garcia RY, Waterman RS, Holmes WC. Current practices of preoperative bowel prepara-tion among North American colorectal surgeons. Clin Infect Dis 1997; 24: 609–619.
- Rocephin® (ceftriaxone sodium) Product Information. Roche Laboratories, Nutley, New Jersey, USA. January, 1998.
- Maxipime® (Cefepime Hydrochloride) Product Information. Bristol-Meyers Squibb Co., Princeton, NJ, USA. May, 1999.
- Yao JDC, Moellering RCJr. Antibacterial agents. In: Murray PR, ed. Manual of Clinical Microbiology, 7th Ed. Washington DC: ASM Press 1999: 1474–1504.
- Beam TR Jr, Gilbert DN, Kunin CM. General guidelines for the evaluation of new anti-infective drugs for the treatment of intra-abdominal infections. European guidelines for the clin-ical evaluation of anti-infective drug products (ESCMID). Wiesbaden: Viewer und Sohn Verlag Gesellschaft, 1993: 59–69.
- Gorbach SL, Condon RE, Conte JE, et al. General guidelines for the evaluation of new anti-infective drugs for prophylaxis of surgical infections. Evaluation of new anti-infec-tive drugs for surgical prophylaxis. Clin Infect Dis 1992; 15(Suppl 1): S313–S338.
- Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. Infect Control Hosp Epidemiol 1994; 15: 463–471.
- Grassi CC, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother 1993; 32( Suppl B): 87-94.
- Kessler RE, Fung-Tomc J. Susceptibility of bacterial iso-lates to 13-lactam antibiotics from US clinical trials over a 5-year period. Am J Med 1996; 100 (Suppl 6A): 13S-19S.
- Sutter VL. In vitro susceptibility of anaerobic and microaerophilic bacteria to metronidazole and its hydroxy metabolite. In: Feingold SM, ed. Proceedings of the First United States Metronidazole Conference. New York: Biomedical Information Corporation: 1982: 61-66.
- Neu HC. Safety of cefepime: a new extended-spectrum cephalosporin. Am J Med 1996; 100 (Suppl 6A): 13S-19S.
- Barbhaiya RH, Forgue ST, Gleason CR, et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother 1990; 34: 1118–1122.
- Bergan T. The pharmacokinetics of metronidazole. In: Feingold SM, ed. Proceedings of the First United States Metronidazole Conference. New York: Biomedical Information Corporation, 1982: 83–112.